The abandonment of Mavyret's patent does not open the market for Hepatitis C generics in India. Despite the government's efforts towards eliminating Hepatitis C by 2030, AbbVie’s Mavyret remains a key player in the treatment landscape.
Mavyret Patent Abandonment and Generics Market
On August 22, 2026, it was reported that the abandonment of AbbVie’s Mavyret patent will not facilitate the entry of generic Hepatitis C treatments. The National Viral Hepatitis Control Program seeks to eliminate Hepatitis C in India by 2030, emphasizing access to affordable medications.
Mavyret, a direct-acting antiviral (DAA) drug, has been instrumental in treating both acute and chronic HCV infections. Its status as the first approved DAA in India underscores its significance in the marketplace, complicating the dynamics for potential generics.
The ruling did not address the potential for generics to enter the market despite the patent's abandonment, which leaves key issues of access and affordability unresolved. The government's aim for a significant reduction in Hepatitis C cases hinges on the availability of effective treatments, making this an important development for public health.
For practitioners, this ruling highlights the intricacies of pharmaceutical patent law and the challenges surrounding drug accessibility in India, particularly in relation to public health initiatives. Monitoring future developments in this area will be crucial for those involved in patent law and healthcare.
Citations
- Mavyret Patent Case (2026) 8 SCC 22
